The Goldman Sachs Group Cuts Seres Therapeutics (NASDAQ:MCRB) Price Target to $0.75
Seres Therapeutics (NASDAQ:MCRB – Free Report) had its price objective trimmed by The Goldman Sachs Group from $1.00 to $0.75 in a report released on Friday,Benzinga reports. The brokerage currently has a sell rating on the biotechnology company’s stock. Several other research firms have also recently issued reports on MCRB. StockNews.com raised Seres Therapeutics from […]
Seres Therapeutics (NASDAQ:MCRB – Free Report) had its price objective trimmed by The Goldman Sachs Group from $1.00 to $0.75 in a report released on Friday,Benzinga reports. The brokerage currently has a sell rating on the biotechnology company’s stock. Several other research firms have also recently issued reports on MCRB. StockNews.com raised Seres Therapeutics from […]
